Product Pipeline for New Pharmaceutical Drugs

OUR MEDICINES IN DEVELOPMENT

Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients. 

Key Innovative Programs

  • Abrocitinib - JAK1 Inhibitor: Atopic Dermatitis
  • Bavencio® (avelumab): Non-Small Cell Lung Cancer, Urothelial Cancer (in collaboration w/Merck KGaA)
  • Braftovi® (encorafinib) + Mektovi® (binimetinib)​: BRAF-mutant metastatic Colorectal Cancer, Melanoma, Non-Small Cell Lung Cancer
  • Duchenne Muscular Dystrophy Gene Therapy
  • fidanacogene elaparvovec (Gene Therapy, coagulation factor IX): Hemophilia
  • giroctocogene fitelparvovec (Gene Therapy, coagulation factor VIII): Hemophilia
  • Next Generation Pneumococcal Conjugate Prophylactic Vaccine: Invasive and Non-Invasive Pneumococcal Infections
  • Prophylactic Vaccine: Clostridioides difficile Infection
  • Prophylactic Vaccine: Respiratory Syncytial Virus Infection (maternal)
  • Ritlecitinib - JAK3/TEC Inhibitor: Alopecia Areata
  • Talzenna® (talazoparib): Prostate Cancer
  • Tanezumab: Chronic Pain due to Moderate-to-Severe Osteoarthritis, Cancer Pain
  • Xeljanz® (tofacitinib): Ankylosing Spondylitis
  • Xtandi® (enzalutamide): Metastatic Castration Sensitive Prostate Cancer, Non-Metastatic High-Risk Castration Sensitive Prostate Cancer

Pipeline Snapshot as of October 27, 2020

  • Discovery Projects
  • Phase 1
    29
  • Phase 2
    36
  • Phase 3
    21
  • Registration
    6
  • Total92
Therapeutic Area
Submission Type
Compound Type
Phase of Development
Compound NameIndicationPhaseSubmission TypeCompound Type
Braftovi (encorafinib) + Mektovi (binimetinib)+ Erbitux® (cetuximab)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
BRAF kinased inhibitor and MEK inhibitor
1st line BRAF-mutant Metastatic Colorectal Cancer Phase 2 Product Enhancement Small Molecule
Ibrance (palbociclib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
CDK 4,6 Kinase Inhibitor
Go to clinical trial
ER+/HER2+ Breast Cancer Phase 3 Product Enhancement Small Molecule
Lorbrena (lorlatinib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
ALK Inhibitor
Go to clinical trial
1st Line ALK Non-Small Cell Lung Cancer (ORPHAN - U.S.) Phase 3 Product Enhancement Small Molecule
PF-05082566
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
CD137 Agonist
Combo w/Kite Pharma'sYescarta (axicabtagene ciloleucel)forCancer Phase 1 New Molecular Entity Biologic
PF-06647020
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
protein tyrosine kinase 7 (PTK7) Targeted Cytotoxicity
Cancer (Biologic) Phase 1 New Molecular Entity Biologic
PF-06804103
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
HER2 Antibody Drug Conjugate
Cancer (Biologic) Phase 1 New Molecular Entity Biologic
PF-06821497
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
EZH2 inhibitor
Cancer Phase 1 New Molecular Entity Small Molecule
PF-06863135
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
BCMA-CD3 Bispecific Antibody
Multiple Myeloma (Biologic) Phase 1 New Molecular Entity Biologic
PF-06873600
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
CDK 2,4,6 inhibitor
Breast Cancer Metastatic Phase 1 New Molecular Entity Small Molecule
PF-06881894, a potential biosimilar to Neulasta® (Pegfilgrastim)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Biosimilar
Business Segment:
Biopharma
Mechanism of Action:
Human Granulocyte Colony Stimulating Factor
Neutropenia in patients undergoing cancer chemotherapy (Biosimilar) (E.U.) Registration Biosimilar Biosimilar
PF-06936308
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Therapeutic Vaccine
Multiple Cancers Phase 1 New Molecular Entity Vaccine
PF-06939999
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
protein arginine methyltransferase 5 (PRMT5) Inhibitor
Solid Tumors Phase 1 New Molecular Entity Small Molecule
PF-06940434
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
Integrin alpha-V/beta-8 Antagonist
Solid Tumors (Biologic) Phase 1 New Molecular Entity Biologic
PF-06952229
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
transforming growth factor, beta receptor 1 (TGFBR1) Inhibitor
Cancer Phase 1 New Molecular Entity Small Molecule
PF-07062119
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
GUCY2c CD3 Bispecific Antibody
Solid Tumors (Biologic) Phase 1 New Molecular Entity Biologic
PF-07104091
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
CDK2 Inhibitor
Breast Cancer Metastatic
Project advanced
Phase 1 New Molecular Entity Small Molecule
PF-07220060
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
CDK4 Inhibitor
Breast Cancer Metastatic
Project advanced
Phase 1 New Molecular Entity Small Molecule
PF-07265807
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
AXL/MERTK Inhibitor
Solid Tumors
Project advanced
Phase 1 New Molecular Entity Small Molecule